Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
NCT05228249 · Fred Hutchinson Cancer Center · PHASE1 · withdrawn · last registry update 2023-01-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.” | – | Registry record, Fred Hutchinson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD19 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-06Results posted on the registry: Juno Therapeutics, a Subsidiary of Celgene, lisocabtagene maraleucel (NCT03744676)
- 2023-11-18Also stopped (terminated): Kite, A Gilead Company, brexucabtagene autoleucel + Fludarabine (NCT03624036)
- 2023-11-07Results posted on the registry: MorphoSys AG, MOR00208 (formerly Xmab 5574) (NCT01685008)
- 2023-11-01Also stopped (withdrawn): Barbara Ann Karmanos Cancer Institute, loncastuximab tesirine (NCT05222438)
- 2023-10-23Results posted on the registry: ADC Therapeutics S.A., Loncastuximab Tesirine + Idelalisib (NCT04699461)
- 2023-10-23Also stopped (terminated): ADC Therapeutics S.A., Loncastuximab Tesirine + Idelalisib (NCT04699461)
- 2023-08-15Also stopped (withdrawn): Epizyme, Inc., Tazemetostat + Tafasitamab (NCT05205252)
- 2023-08-14Phase 3 first posted: University of Birmingham, Odronextamab + Loncastuximab tesirine (NCT05991388)
- 2023-06-05Phase 3 first posted: Novartis Pharmaceuticals, Tisagenlecleucel + Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles. (NCT05888493)
- 2023-05-12Also stopped (terminated): Pack Health, a drug against CD19 (NCT05199961)
- 2023-05-06Also stopped (terminated): University of Cologne, CTL019 (NCT04161118)
- 2023-03-27Phase 3 first posted: Zenas BioPharma (USA), LLC, Obexelimab + Obexelimab (NCT05786573)
- 2023-03-09Also stopped (withdrawn): Novartis Pharmaceuticals, Tisagenlecleucel (NCT04156659)
- 2023-02-17Results posted on the registry: M.D. Anderson Cancer Center, Blinatumomab + Dexamethasone (NCT03121534)
- 2023-02-17Also stopped (terminated): M.D. Anderson Cancer Center, Blinatumomab + Dexamethasone (NCT03121534)
- 2023-01-31Also stopped (terminated): Novartis Pharmaceuticals, Tisagenlecleucel + Ibrutinib (NCT03876028)
- 2023-01-30Also stopped (terminated): Novartis Pharmaceuticals, Tisagenlecleucel (NCT04225676)
- 2023-01-25Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Dasatinib (NCT02143414)
- 2023-01-20Results posted on the registry: M.D. Anderson Cancer Center, Blinatumomab (NCT02807883)
- 2022-12-29Results posted on the registry: Juno Therapeutics, a Subsidiary of Celgene, lisocabtagene maraleucel (NCT03483103)
- 2022-12-23Phase 3 first posted: Nektar Therapeutics, NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg (NCT05664217)
- 2022-12-22Phase 3 first posted: Zenas BioPharma (USA), LLC, Obexelimab (NCT05662241)
- 2022-12-06Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Blinatumomab (NCT02101853)
- 2022-11-04Phase 3 first posted: Kite, A Gilead Company, Axicabtagene Ciloleucel + Cyclophosphamide (NCT05605899)
- 2022-11-04Results posted on the registry: M.D. Anderson Cancer Center, Blinatumomab + Cyclophosphamide (NCT03518112)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision